Next-Gen Technology Who Can Summarize Complex Cancer Pathology Reports Better? AI or Doctors?
Source: Press release
Northwestern University
3 min Reading Time
A new study tested six AI models developed by Meta, Google, Deepseek and Mistral AI and found that AI models can generate more complete summaries of complex cancer pathology reports than physicians.
Study senior author Dr. Mohamed Abazeed demonstrates a prototype AI tool that summarizes cancer pathology reports, shown here in a radiation oncology setting. The tool, developed at Northwestern Medicine, is not yet in clinical use and is undergoing further testing.
(Source: Northwestern University)
Chicago/USA – AI models can generate more complete summaries of complex cancer pathology reports than physicians, according to a new Northwestern Medicine study that tested six models developed by Meta, Google, Deepseek and Mistral AI.
The study was published on April 8 in JCO Clinical Cancer Informatics, a journal from the American Society of Clinical Oncology.
The findings offer a potential fix to a growing challenge in oncology. As biomarker testing expands, and patients live longer, pathology reports have become increasingly detailed and longitudinal, often spanning multiple institutions and requiring clinicians to synthesize large volumes of information under significant time pressure.
In this study, several open-source AI models consistently produced summaries that were more comprehensive than physician-written versions, particularly in capturing molecular and genetic findings that are critical for treatment decisions.
“As cancer care becomes increasingly complex, the burden of synthesizing complex reports is growing rapidly,” said senior study author Dr. Mohamed Abazeed, chair and professor of radiation oncology at Northwestern University Feinberg School of Medicine. “What we’re seeing is that AI can help ensure critical pathological and genomic details are consistently captured — not as a replacement for physicians, but as a tool to augment clinical decision-making.”
How the study was conducted
The Northwestern investigators analyzed 94 de-identified pathology reports from lung cancer patients. These reports included detailed text describing:
The AI models analyzed the text content of these reports and generated structured summaries.
The AI-generated summaries were compared to clinical summaries previously written by physicians. A panel of oncologists assessed each summary for accuracy, completeness, conciseness and potential clinical risk. Across models, AI-generated summaries were consistently rated as more complete, with the largest differences observed in the inclusion of molecular and genomic findings.
“If AI can reliably synthesize these reports, clinicians can review key findings more efficiently, important genetic details are less likely to be overlooked and documentation becomes more standardized,” said study co-author Troy Teo, instructor of radiation oncology at Feinberg. “This could help physicians focus more on patient care.”
Llama 3.1 and Deepseek performed best
The scientists evaluated six open-source language models: Meta’s Llama 3.0, 3.1 and 3.2 models, Google’s Gemma 9B, Mistral 7.2B and Deepseek-R1. These are not chatbots like ChatGPT, but systems that researchers can download and run locally. According to the study, the strongest performers were Deepseek and Llama 3.1.
The Northwestern team is now developing an app using Llama 3.1 to eventually allow physicians to upload pathology reports and receive AI-generated summaries for their review. But the study authors emphasize that before deploying the app, they need more testing and validation studies.
AI as a second-opinion tool
The authors said they envision AI as a support layer that enhances, rather than replaces, clinical expertise. It could help highlight key findings, identify missing information and improve consistency in documentation.
“Patients with complex cancers might benefit the most,” said study first author Dr. Yirong Liu, a fifth-year resident in radiation oncology at McGaw Medical Center of Northwestern. “In cases where missing a key pathological finding or an actionable genetic marker could change treatment decisions, ensuring that information is consistently captured is critical.”
“Patients are living longer and undergoing repeated biopsies and genetic sequencing,” Liu added. “Their reports can span dozens of pages. Even a single missed detail can impact care, and this is where AI may provide meaningful support.”
The study is titled “Toward Automating the Summarization of Cancer Pathology Reports Using Large Language Models to Improve Clinical Usability.” Troy Teo received funding from the Canadian Institute of Health Research (grant CIHR-472392) and from Amazon Web Services’ Social Impact funding.
Date: 08.12.2025
Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.
Consent to the use of data for promotional purposes
I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planck-Str. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here
Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.
Additionally, my consent also includes the processing of my email address and telephone number for data matching for marketing purposes with select advertising partners such as LinkedIn, Google, and Meta. For this, Vogel Communications Group may transmit said data in hashed form to the advertising partners who then use said data to determine whether I am also a member of the mentioned advertising partner portals. Vogel Communications Group uses this feature for the purposes of re-targeting (up-selling, cross-selling, and customer loyalty), generating so-called look-alike audiences for acquisition of new customers, and as basis for exclusion for on-going advertising campaigns. Further information can be found in section “data matching for marketing purposes”.
In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here. This does not apply to data matching for marketing purposes.
Right of revocation
I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://contact.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.